Pfizer faces more pressure after Sutent fails lung cancer trial
This article was originally published in Scrip
Executive Summary
Pfizer is facing further disappointment with Sutent (sunitinib), after the multi-targeted kinase inhibitor failed to improve overall survival in a pivotal Phase III trial in patients with previously treated non-small cell lung cancer (NSCLC).